Routine serum thyroid-stimulating hormone testing-optimizing pre-conception health or generating toxic knowledge?

Abha Maheshwari, Priya Bhide, Jyotsna Pundir, Siladitya Bhattacharya

Research output: Contribution to journalComment/debate

2 Citations (Scopus)

Abstract

Monitoring subclinical hypothyroidism (SCH) in women is believed to be important in terms of preventing overt hypothyroidism and optimizing the health and cognitive development of their children. Current systematic reviews have suggested an association between maternal SCH and adverse obstetric and neonatal outcomes. However, initiating the administration of thyroxine during pregnancy has failed to demonstrate appreciable health benefits. Hence there are calls by professional endocrine societies for optimizing serum thyroid-stimulating hormone (TSH) levels pre-conception. The strategy of ensuring that serum TSH levels are below 2.5 mIU/l during the pre-conception period has generated considerable uncertainty partly because the recommended level of

Original languageEnglish
Pages (from-to)1779-1785
Number of pages7
JournalHuman Reproduction
Volume32
Issue number9
Early online date12 Jul 2017
DOIs
Publication statusPublished - Sep 2017

Keywords

  • subclinical hypothyroidism
  • pre-conception
  • TSH
  • pregnancy
  • fertility
  • ASSISTED REPRODUCTION TECHNOLOGIES
  • POPULATION-BASED COHORT
  • SUBCLINICAL HYPOTHYROIDISM
  • LEVOTHYROXINE TREATMENT
  • PREGNANT-WOMEN
  • DISEASE
  • MANAGEMENT
  • CHILDHOOD
  • HYPOTHYROXINEMIA
  • ASSOCIATION

Cite this

Routine serum thyroid-stimulating hormone testing-optimizing pre-conception health or generating toxic knowledge? / Maheshwari, Abha; Bhide, Priya; Pundir, Jyotsna; Bhattacharya, Siladitya.

In: Human Reproduction, Vol. 32, No. 9, 09.2017, p. 1779-1785.

Research output: Contribution to journalComment/debate

@article{640738d8a2824ac4b604a70ed6678afc,
title = "Routine serum thyroid-stimulating hormone testing-optimizing pre-conception health or generating toxic knowledge?",
abstract = "Monitoring subclinical hypothyroidism (SCH) in women is believed to be important in terms of preventing overt hypothyroidism and optimizing the health and cognitive development of their children. Current systematic reviews have suggested an association between maternal SCH and adverse obstetric and neonatal outcomes. However, initiating the administration of thyroxine during pregnancy has failed to demonstrate appreciable health benefits. Hence there are calls by professional endocrine societies for optimizing serum thyroid-stimulating hormone (TSH) levels pre-conception. The strategy of ensuring that serum TSH levels are below 2.5 mIU/l during the pre-conception period has generated considerable uncertainty partly because the recommended level of",
keywords = "subclinical hypothyroidism, pre-conception, TSH, pregnancy, fertility, ASSISTED REPRODUCTION TECHNOLOGIES, POPULATION-BASED COHORT, SUBCLINICAL HYPOTHYROIDISM, LEVOTHYROXINE TREATMENT, PREGNANT-WOMEN, DISEASE, MANAGEMENT, CHILDHOOD, HYPOTHYROXINEMIA, ASSOCIATION",
author = "Abha Maheshwari and Priya Bhide and Jyotsna Pundir and Siladitya Bhattacharya",
note = "Funding No external funding was sought to prepare this manuscript.",
year = "2017",
month = "9",
doi = "10.1093/humrep/dex240",
language = "English",
volume = "32",
pages = "1779--1785",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "OXFORD UNIV PRESS",
number = "9",

}

TY - JOUR

T1 - Routine serum thyroid-stimulating hormone testing-optimizing pre-conception health or generating toxic knowledge?

AU - Maheshwari, Abha

AU - Bhide, Priya

AU - Pundir, Jyotsna

AU - Bhattacharya, Siladitya

N1 - Funding No external funding was sought to prepare this manuscript.

PY - 2017/9

Y1 - 2017/9

N2 - Monitoring subclinical hypothyroidism (SCH) in women is believed to be important in terms of preventing overt hypothyroidism and optimizing the health and cognitive development of their children. Current systematic reviews have suggested an association between maternal SCH and adverse obstetric and neonatal outcomes. However, initiating the administration of thyroxine during pregnancy has failed to demonstrate appreciable health benefits. Hence there are calls by professional endocrine societies for optimizing serum thyroid-stimulating hormone (TSH) levels pre-conception. The strategy of ensuring that serum TSH levels are below 2.5 mIU/l during the pre-conception period has generated considerable uncertainty partly because the recommended level of

AB - Monitoring subclinical hypothyroidism (SCH) in women is believed to be important in terms of preventing overt hypothyroidism and optimizing the health and cognitive development of their children. Current systematic reviews have suggested an association between maternal SCH and adverse obstetric and neonatal outcomes. However, initiating the administration of thyroxine during pregnancy has failed to demonstrate appreciable health benefits. Hence there are calls by professional endocrine societies for optimizing serum thyroid-stimulating hormone (TSH) levels pre-conception. The strategy of ensuring that serum TSH levels are below 2.5 mIU/l during the pre-conception period has generated considerable uncertainty partly because the recommended level of

KW - subclinical hypothyroidism

KW - pre-conception

KW - TSH

KW - pregnancy

KW - fertility

KW - ASSISTED REPRODUCTION TECHNOLOGIES

KW - POPULATION-BASED COHORT

KW - SUBCLINICAL HYPOTHYROIDISM

KW - LEVOTHYROXINE TREATMENT

KW - PREGNANT-WOMEN

KW - DISEASE

KW - MANAGEMENT

KW - CHILDHOOD

KW - HYPOTHYROXINEMIA

KW - ASSOCIATION

U2 - 10.1093/humrep/dex240

DO - 10.1093/humrep/dex240

M3 - Comment/debate

VL - 32

SP - 1779

EP - 1785

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 9

ER -